Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

Growth Factor Receptors: PDGF, TGF-Beta, VEGF, EGF and IGF-1

Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 21 de octubre de 2026

Growth factor receptors are the cell-surface proteins through which cells read polypeptide growth factors such as PDGF, VEGF, EGF, IGF-1 and TGF-beta. The first four act on receptor tyrosine kinases, single-pass transmembrane receptors that direct growth, differentiation, metabolism and motility.^[1][2] TGF-beta acts on a pair of transmembrane serine/threonine kinases, receptors I and II.^[3]

Platelets store many of these ligands. Blair and Flaumenhaft list VEGF, PDGF, EGF and IGF among the growth factors held in alpha granules, which fuse with the plasma membrane on activation and release hundreds of bioactive proteins.^[4] Platelets also release TGF-beta1 in a latent form.^[5]

This reference follows each receptor family from ligand binding to its first signaling steps. It closes with the binding, phosphorylation and reporter assays that laboratories use to measure receptor activation.

Understanding receptor tyrosine kinase architecture and ligand-induced dimerization

Each receptor tyrosine kinase has a ligand-binding extracellular region, one transmembrane helix and an intracellular tyrosine kinase domain (Fig. 1).^[1][6] Ligand binding brings two receptors together, and dimerization leads to autophosphorylation on specific tyrosine residues.^[6]

Lemmon and Schlessinger note that the strategies by which ligands induce dimerization are surprisingly diverse, as are the mechanisms that couple dimerization to kinase activation.^[2] PDGF bridges two receptors with its own dimeric body, and EGF changes the receptor shape so that the receptors contact each other directly.^[7][8]

Autophosphorylation raises kinase activity and creates docking sites for signaling proteins that carry SH2 domains.^[6] Hubbard and Miller describe these receptors as essential components of the pathways that mediate cell-to-cell communication.^[1]

PDGF dimers clamp PDGFR-beta at their dimerization seam

PDGFs and their receptors have served as prototypes for growth factor and receptor tyrosine kinase function for more than 25 years.^[9] In animal development, PDGFR-alpha signaling takes part in gastrulation and in forming the neural crest, lung, intestine, skin and skeleton, and PDGFR-beta signaling in blood vessel formation and early hematopoiesis.^[9]

PDGFR-alpha and PDGFR-beta are type III receptor tyrosine kinases, with five Ig-like domains outside the cell and a split kinase domain inside.^[6] The human PDGFRB gene maps to chromosome 5q32.^[10]

Shim and colleagues solved PDGF-B bound to the first three Ig domains of PDGFR-beta and found that the two PDGF-B protomers clamp the receptor at their dimerization seam (Fig. 2).^[7] The interface is predominantly hydrophobic, and the PDGF-B L1 loop, disordered in the free growth factor, adopts a defined conformation to contact the third Ig domain.^[7]

In the same study, PDGF propeptides occupied positions on the mature growth factor that overlap the receptor sites, which the authors read as a way to cover hydrophobic surfaces during secretion.^[7] Calorimetry showed that the membrane-proximal contact between PDGFR-alpha molecules, required for activation, contributes negatively to ligand binding.^[7]

EGF binding exposes a dimerization arm on EGFR

Ogiso and colleagues solved a 2:2 complex of human EGF with the EGFR extracellular region at 3.3 Å resolution. Domains I to III form a C shape, with EGF docked between domains I and III (Fig. 3).^[8] The human EGFR gene maps to chromosome 7p11.2.^[11]

The 1:1 complexes dimerize through a direct receptor contact: a protruding beta-hairpin arm of each domain II holds the body of the other, and mutagenesis confirmed this receptor-mediated dimerization.^[8] Lemmon, Schlessinger and Ferguson describe it as distinctive to the EGFR family, with ligand binding inducing a dramatic conformational change that exposes the arm.^[12]

An asymmetric kinase dimer switches the EGFR kinase on

Zhang and colleagues found that the EGFR kinase domain is intrinsically autoinhibited, in a conformation that resembles Src and the cyclin-dependent kinases.^[13] Activation comes from an asymmetric dimer in which the C-terminal lobe of one kinase domain plays the role that cyclin plays in an active CDK and cyclin complex.^[13]

In this family, allosteric changes in the asymmetric dimer drive kinase regulation, and the intracellular juxtamembrane segment activates the receptor.^[12] A long carboxy-terminal tail carries the autophosphorylation sites and serves an autoregulatory function.^[12]

VEGF-A signals through VEGFR-1, VEGFR-2 and neuropilin coreceptors

Five mammalian VEGF ligands act through three receptor tyrosine kinases, and coreceptors such as neuropilins and integrins associate with the ligand and receptor complex to modulate its output.^[14] VEGF-A binds two of these receptors, KDR (VEGFR-2) and Flt-1 (VEGFR-1).^[15]

VEGF-A is a homodimeric cystine knot growth factor whose closest relative is PDGF. Muller and colleagues refined its receptor-binding domain to 1.93 Å with eight copies in the asymmetric unit, and mutagenesis placed one flexible loop in the receptor-binding site (Fig. 4).^[15]

The VEGF receptor extracellular region holds seven immunoglobulin homology domains, and ligand binding promotes receptor dimerization.^[16] Leppänen and colleagues located the high-affinity VEGFR-2 binding site in domains D2 and D3, and VEGFR-1 and VEGFR-2 chimeras defined the VEGFR-2 residues critical for binding VEGF-A and VEGF-C.^[16] The human KDR gene maps to chromosome 4q12.^[17]

Simons, Gordon and Claesson-Welsh describe VEGFR-2 signaling as tightly regulated at several levels: by neuropilins, proteoglycans, integrins and protein tyrosine phosphatases, and by receptor endocytosis and trafficking.^[18] VEGFs and their receptors balance the formation of new blood vessels with the upkeep of existing ones, in development and in adult tissues.^[18]

Platelets sort VEGF into its own granules. Italiano and colleagues found VEGF and endostatin in separate alpha-granule subpopulations, and a selective PAR4 agonist released the endostatin-containing granules while the VEGF-containing granules stayed in the platelet.^[19]

IGF-1 binding releases an autoinhibited IGF-1R homodimer

The type 1 insulin-like growth factor receptor is a homodimeric receptor tyrosine kinase that signals into pathways directing normal cellular growth, differentiation and proliferation.^[20] The human IGF1R gene maps to chromosome 15q26.3.^[21]

Xu and colleagues solved crystal structures of the IGF-1R ectodomain alone and bound to IGF-I. The structures show the growth factor at the primary ligand-binding site and indicate that binding separates receptor domains by induced fit.^[20]

Kavran and colleagues found that the IGF1R ectodomain maintains an autoinhibited state with the transmembrane helices held apart. Ligand binding releases this constraint, letting the transmembrane segments associate and the intracellular regions autophosphorylate.^[22]

Phosphorylated IGF1R was fully active independent of ligand and of the extracellular and transmembrane regions, so the authors identify autophosphorylation as the key step that ligand binding triggers.^[22] The active receptor then phosphorylates insulin receptor substrates and SHC.^[23]

TGF-beta is stored in latent form and signals through serine/threonine kinase receptors

Assoian and colleagues identified platelets in 1983 as a major storage site of TGF-beta, a 25,000-dalton protein of two disulfide-linked 12,500-dalton subunits. The platelet extract had a specific activity 100-fold greater than the other normal tissues tested.^[24]

TGF-beta is stored in the extracellular matrix as a latent complex with its prodomain, held there by latent TGF-beta binding proteins (Fig. 5).^[25] Robertson and Rifkin review the molecules that set its bioavailability and note that TGF-beta must be activated before it can bind its receptors.^[26]

Shi and colleagues solved porcine proTGF-beta1 as a ring-shaped dimer in which the prodomain shields the growth factor from receptors. Activation required alpha-v integrin binding to an RGD sequence in the prodomain and force that unfastens a straitjacket around each growth factor monomer.^[25]

Platelets carry an activation route of their own. Blakytny and colleagues found that thrombin-stimulated platelets activated a significant proportion of the latent TGF-beta they released, through a released furin-like proprotein convertase.^[5]

Receptor II recruits and phosphorylates receptor I

Wrana and colleagues showed in 1994 that TGF-beta binds directly to receptor II, a constitutively active kinase. Receptor I then recognizes the bound ligand, joins the complex and is phosphorylated by receptor II, which lets it pass the signal to downstream substrates.^[3]

The genes encoding the two receptors, TGFBR1 and TGFBR2, map to chromosomes 9q22.33 and 3p24.1.^[27][28] Heldin and Moustakas describe the active signaling unit as a heterotetrameric complex of type I and type II receptors.^[29]

Radaev and colleagues solved human TGF-beta1 with the extracellular domains of both receptors at 3.0 Å (Fig. 6). Binding of all three TGF-beta isoforms to the type I receptor rose considerably in the presence of the type II receptor.^[30]

Hinck, Mueller and Springer trace the growth factor domain of the TGF-beta family to a common cystine knot ancestor. They describe how ternary complexes show TGF-beta growth factor dimers binding type I and type II receptors at the cell surface.^[31]

SMAD proteins carry the signal to the nucleus

After receptor activation, SMAD2 and SMAD3 are phosphorylated and form complexes with SMAD4, which move to the nucleus and control expression of target genes.^[32][33] Shi and Massagué review this route from ligand binding to transcriptional regulation and the control of SMAD activity and degradation.^[33]

TGF-beta receptors also signal through non-SMAD pathways, including the ERK1/2, JNK and p38 MAP kinases, Src, PI3K and Rho GTPases.^[29] Massagué frames the central question of the field as how context determines the cellular response to TGF-beta.^[34]

Phosphotyrosine docking sites route signals to the MAPK, PI3K and PLC-gamma pathways

SH2 domains recognize phosphotyrosine within particular sequence motifs. Bae and colleagues noted that the modest affinity of SH2 domains for phosphotyrosine peptides likely gives an oversimplified account of how cells select signaling pathways.^[35]

Their crystal structure of the activated FGFR1 kinase with a phospholipase C-gamma fragment showed a secondary binding site on an SH2 domain contacting the kinase domain. This phosphorylation-independent contact set the selectivity of phospholipase C-gamma binding and signaling in cultured cells.^[35]

At IGF-1R, phosphotyrosines on IRS proteins and SHC recruit the p85 subunit of PI3K, GRB2 and SHP2, which lead into the PI3K and Ras-MAP kinase pathways.^[23] Hakuno and Takahashi note that these pathways are required for IGF-induced cell proliferation, differentiation and survival.^[23]

PDGF receptors use the same logic: their SH2-docking pathways promote cell growth, survival and migration.^[6] The table summarizes the receptors on this page.

Binding, phosphorylation and reporter assays measure receptor activation

Binding studies measure the first step. Shim and colleagues used calorimetry on PDGF and its receptor, and Radaev and colleagues used quantitative binding studies to compare receptor kinetics across the TGF-beta isoforms.^[7][30]

Receptor chimeras map specificity: Leppänen and colleagues swapped regions between VEGFR-1 and VEGFR-2 to find the residues that bind VEGF-A.^[16] Kinase activation is read as phosphorylation, and Kavran and colleagues measured it in full-length IGF1R and in kinase-containing fragments.^[22]

Reporter constructs read the transcriptional output. Dennler and colleagues identified CAGA boxes in the human PAI-1 promoter that bind SMAD3 and SMAD4, and these boxes conferred TGF-beta and activin responsiveness on a heterologous promoter reporter construct.^[32]

On the ligand side, mass spectrometry defines what platelets store. Maynard and colleagues identified 284 proteins in a fraction enriched for alpha granules, 44 of them newly assigned to the granule, and confirmed several by immunoelectron microscopy.^[36]

Where to go from here

The platelet granule biology reference describes how alpha granules form, what they hold and how activation releases them. The PRP preparation variables reference explains how spin settings, anticoagulant and activation shape the growth factor content of a preparation, and the platelet-rich fibrin reference follows the fibrin matrix that holds and releases these proteins.

The BMAC and SVF composition reference and the platelet study reporting reference complete the cluster, and the MSC secretome reference covers the same growth factors from stromal cells. Our research methods, regulatory and quality references support study design and documentation, and our team is glad to discuss the methods described on this page.